Immediate Impact
4 by Nobel laureates 2 from Science/Nature 62 standout
Citing Papers
Cross-priming in cancer immunology and immunotherapy
2025 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of Irene Moreno being referenced
1025MO First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Irene Moreno | 173 | 56 | 102 | 83 | 35 | 295 | |
| Diana D. Shi | 92 | 47 | 88 | 79 | 32 | 305 | |
| Yuxiang Deng | 165 | 71 | 72 | 64 | 33 | 330 | |
| Yanli Xiong | 114 | 100 | 48 | 157 | 34 | 324 | |
| Jake Jacob | 115 | 65 | 61 | 93 | 23 | 311 | |
| Moritz Maas | 138 | 96 | 135 | 95 | 27 | 323 | |
| Nian‐Nian Zhong | 93 | 49 | 40 | 85 | 36 | 273 | |
| Guoliang Zheng | 83 | 120 | 114 | 91 | 30 | 284 | |
| Shachar Laks | 174 | 48 | 75 | 63 | 36 | 267 | |
| Arjun K. Menta | 141 | 69 | 76 | 54 | 32 | 311 | |
| Zezhou Wang | 67 | 59 | 58 | 100 | 28 | 333 |
All Works
Login with ORCID to disown or claim papers
Loading papers...